Key result
In chronic heart failure, the PDE5 TT genotype was associated with a 33% decrease in pulmonary vascular resistance with inhaled nitric oxide, compared to 1.6% for GG and 0% for GT.
Why the study?
Does the hemodynamic response to inhaled nitric oxide depend on the PDE5 G(-1142)T polymorphism in patients with chronic heart failure?
Observational (n=72)
Does the hemodynamic response to inhaled nitric oxide depend on the PDE5 G(-1142)T polymorphism in patients with chronic heart failure?
The PDE5 G(-1142)T polymorphism significantly influences the pulmonary vascular resistance response to inhaled nitric oxide in patients with chronic heart failure.
Answers are grounded in this paper and cite their sources.
PDE5 TT genotype may enhance nitric oxide responsiveness in chronic heart failure; leaves open whether genotyping should guide therapy.
To evaluate the vasoconstrictor component of PH in CHF by investigating the hemodynamic response to inhaled nitric oxide (iNO) and to determine whether this response was influenced by the phosphodiesterase 5 gene (PDE5) G(1142)T polymorphism. CHF patients underwent right heart catheterization at rest and after 20 ppm of iNO and plasma cGMP and PDE5 G(1142)T polymorphism determinations. Of the 72 included CHF patients (mean age, 53±1 years; mean left ventricular ejection fraction, 29±1%; and mean pulmonary artery pressure, 25.5±1.3 mmHg), 54% had ischemic heart disease. Proportions of patients with the TT, GT, and GG genotypes were 39%, 42% and 19% respectively. Baseline hemodynamic characteristics were not significantly different across PDE5 genotype groups, although pulmonary capillary wedge pressure (PCWP) tended to be lower in the TT group (P=0.09). Baseline plasma cGMP levels were significantly lower in the TT than in the GG and GT patients. With iNO, PVR diminished in TT (-33%) but not GG (-1.6%) or GT (0%) patients (P=0.002); and PCWP increased more in TT than in GT (P<0.05) or GG (P<0.003) patients. The PDE5 G(-1142) polymorphism is therefore a major contributor to the iNO-induced PVR decrease in CHF.
No takes yet. Share an insight, caveat, or question.
Damy et al. (2011) conducted an observational in Chronic Heart Failure (n=72). PDE5 G(-1142)T polymorphism (TT genotype) vs. GG and GT genotypes was evaluated on Change in pulmonary vascular resistance (PVR) with inhaled nitric oxide (p=0.002). In chronic heart failure, the PDE5 TT genotype was associated with a 33% decrease in pulmonary vascular resistance with inhaled nitric oxide, compared to 1.6% for GG and 0% for GT.
Synapse has enriched 10 related papers. Consider them for comparative context: